CN1688511A - Rare earth metal compounds, methods of making, and methods of using the same - Google Patents
Rare earth metal compounds, methods of making, and methods of using the same Download PDFInfo
- Publication number
- CN1688511A CN1688511A CN 03824117 CN03824117A CN1688511A CN 1688511 A CN1688511 A CN 1688511A CN 03824117 CN03824117 CN 03824117 CN 03824117 A CN03824117 A CN 03824117A CN 1688511 A CN1688511 A CN 1688511A
- Authority
- CN
- China
- Prior art keywords
- compound
- lanthanum
- rare earth
- oxycarbonate
- phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- 150000002909 rare earth metal compounds Chemical class 0.000 title abstract description 11
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 103
- 239000010452 phosphate Substances 0.000 claims abstract description 96
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 90
- 229910052746 lanthanum Inorganic materials 0.000 claims abstract description 81
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims abstract description 80
- 239000002245 particle Substances 0.000 claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 239000012530 fluid Substances 0.000 claims abstract description 18
- 229910052751 metal Inorganic materials 0.000 claims abstract description 11
- 239000002184 metal Substances 0.000 claims abstract description 11
- 201000005991 hyperphosphatemia Diseases 0.000 claims abstract description 7
- 229910052684 Cerium Inorganic materials 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 229910052727 yttrium Inorganic materials 0.000 claims abstract description 4
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 105
- 239000000243 solution Substances 0.000 claims description 81
- 239000000047 product Substances 0.000 claims description 51
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 42
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 32
- 150000002604 lanthanum compounds Chemical class 0.000 claims description 27
- 239000013078 crystal Substances 0.000 claims description 26
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims description 24
- 150000002910 rare earth metals Chemical class 0.000 claims description 23
- -1 rare earth compound Chemical class 0.000 claims description 22
- 229910002226 La2O2 Inorganic materials 0.000 claims description 19
- 238000001354 calcination Methods 0.000 claims description 19
- JEROREPODAPBAY-UHFFFAOYSA-N [La].ClOCl Chemical compound [La].ClOCl JEROREPODAPBAY-UHFFFAOYSA-N 0.000 claims description 18
- 238000001704 evaporation Methods 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 18
- 230000008020 evaporation Effects 0.000 claims description 17
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 claims description 17
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 16
- 238000010304 firing Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 12
- 238000001179 sorption measurement Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 7
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 claims description 6
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 claims description 6
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- 239000012527 feed solution Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000009834 vaporization Methods 0.000 claims description 3
- 230000008016 vaporization Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 239000000413 hydrolysate Substances 0.000 claims 3
- 239000012266 salt solution Substances 0.000 claims 3
- 239000007795 chemical reaction product Substances 0.000 claims 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 49
- 229910001868 water Inorganic materials 0.000 abstract description 44
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 12
- 229910021645 metal ion Inorganic materials 0.000 abstract description 5
- 150000002739 metals Chemical class 0.000 abstract description 4
- 229910001463 metal phosphate Inorganic materials 0.000 abstract description 3
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000021317 phosphate Nutrition 0.000 description 81
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 33
- 229910052698 phosphorus Inorganic materials 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 25
- 239000011574 phosphorus Substances 0.000 description 25
- 239000013067 intermediate product Substances 0.000 description 24
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 20
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 20
- 229960001633 lanthanum carbonate Drugs 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 239000011550 stock solution Substances 0.000 description 14
- 229910002249 LaCl3 Inorganic materials 0.000 description 13
- 238000001878 scanning electron micrograph Methods 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 238000002441 X-ray diffraction Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000009257 reactivity Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 229910017583 La2O Inorganic materials 0.000 description 9
- 230000029142 excretion Effects 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- JLRJWBUSTKIQQH-UHFFFAOYSA-K lanthanum(3+);triacetate Chemical compound [La+3].CC([O-])=O.CC([O-])=O.CC([O-])=O JLRJWBUSTKIQQH-UHFFFAOYSA-K 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 229910052785 arsenic Inorganic materials 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 5
- AFCUGQOTNCVYSW-UHFFFAOYSA-H lanthanum(3+);tricarbonate;hydrate Chemical compound O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O AFCUGQOTNCVYSW-UHFFFAOYSA-H 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011669 selenium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 150000002484 inorganic compounds Chemical class 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 238000004438 BET method Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 238000013059 nephrectomy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229910052787 antimony Inorganic materials 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XFVGXQSSXWIWIO-UHFFFAOYSA-N chloro hypochlorite;titanium Chemical compound [Ti].ClOCl XFVGXQSSXWIWIO-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical class ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- LQFNMFDUAPEJRY-UHFFFAOYSA-K lanthanum(3+);phosphate Chemical compound [La+3].[O-]P([O-])([O-])=O LQFNMFDUAPEJRY-UHFFFAOYSA-K 0.000 description 2
- 229910052745 lead Inorganic materials 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000011817 metal compound particle Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- KTUFCUMIWABKDW-UHFFFAOYSA-N oxo(oxolanthaniooxy)lanthanum Chemical compound O=[La]O[La]=O KTUFCUMIWABKDW-UHFFFAOYSA-N 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 229910002420 LaOCl Inorganic materials 0.000 description 1
- 229910001477 LaPO4 Inorganic materials 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229910010270 TiOCl2 Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- LULLIKNODDLMDQ-UHFFFAOYSA-N arsenic(3+) Chemical compound [As+3] LULLIKNODDLMDQ-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940116314 ketaject Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical group [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003609 titanium compounds Chemical class 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Sample (I) | Compound (I) | In the manufacturing method Corresponding example number | BET surface area Product m2/g | Left after 10 minutes The remaining PO4Score of | Initial first order rate Constant K1(min-1) |
1 2 3 4 5 6 7 8 9 10 | La2O(CO3)2·xH2O La2O(CO3)2·xH2O La2O(CO3)2·xH2O La2CO5(4h grinding) La2O2CO3 La2CO5(2h grinding) La2O2CO3 La2CO5(No grinding) La2(CO3)3·4H2O La2(CO3)3·1H2O | 11 11 11 7 5 7 7 5 Industrial sample Industrial process | 41.3 35.9 38.8 25.6 18 18.8 16.5 11.9 4.3 2.9 | 0.130 0.153 0.171 0.275 0.278 0.308 0.327 0.483 0.623 0.790 | 0.949 0.929 0.837 0.545 0.483 0.391 0.36 0.434 0.196 0.094 |
Lanthanum oxycarbonate compounds | Intermediate phosphorus/creatinine ratio (and % reduction of the amount of the drug before dispensing | 10 th and 90 th percentiles |
A | 48.4% | 22.6-84.4% |
B | 37.0% | -4.1-63.1% |
La oxycarbonate to be tested Compound (I) | Curve line0-72hLower average (sd) plane Volume (ng.h/ml) (standard deviation) | Maximum concentration Cmax (ng/ml); (Standard deviation) |
A | 54.6(28.0) | 2.77(2.1) |
B | 42.7(34.8) | 2.45(2.2) |
Group of ID | Treatment of | Experimental items | Sigmacell cellulose | Teklad diet |
I | Negative control | 0.0% | 1.2% | 98.8% |
II | Compound B-intermediate level | 0.3% | 0.9% | 98.8% |
III | Compound B-high levels | 0.6% | 0.6% | 98.8% |
IV | Compound C-intermediate level | 0.3% | 0.9% | 98.8% |
V | Compound C-high level | 0.6% | 0.6% | 98.8% |
Urinary phosphate excretion (mg/day) | |
Comparison of | 4.3 |
Compound B ═ La2O2CO3 | 2.3 |
Compound C ═ La2CO5 | 1.9 |
Experiment ID | Compound (I) | |
1 | La2O3 | Industrial (Prochem) La was treated at 850 deg.C2(CO3)
3·H2O roasting for 16 |
2 | La2CO5 | Lanthanum acetate solution was spray dried at 600 deg.C Prepared by calcining at ambient temperature for 7 hours (corresponding to the method of FIG. 3) |
3 | LaOCl | Lanthanum chloride solution was spray dried and brought to 700 deg.C Calcining at room temperature for 10 hours (corresponding to the method of FIG. 1) |
4 | La2(CO3)3·4H2O | Purchased from Prochem (comparative example) |
5 | Carbonic acid Ti | Prepared by the process of FIG. 11, wherein LaCl3For solutions TiOCl2The solution was replaced. |
6 | TiO2 | Preparation by addition of sodium chloride using the method corresponding to FIG. 2 |
7 | La2O(CO3)2·xH2O | Sodium carbonate is added to a lanthanum chloride solution at 80 degrees centigrade In (1), precipitation (corresponding to the method of FIG. 10) |
8 | La2O2CO3 | Adding sodium carbonate solution to lanthanum chloride at 80 deg.C Precipitating in solution, and calcining at 500 deg.C for 3 Hours (method of FIG. 11) |
Removed analytes% Sb As Be Cd Ca Cr Co Cu Fe Pb Mg Mn Mo Ni Se Tl Ti V Zn Al Ba B Ag P | ||||||||||||||||||||||||
La2O3 | 89 | 85 | 97 | 95 | 21 | 100 | 69 | 89 | 92 | 92 | 0 | 98 | 89 | 28 | 72 | 8 | 90 | 95 | 95 | 85 | 23 | 0 | 47 | 96 |
La2CO5 | 96 | 93 | 100 | 83 | 0 | 100 | 52 | 97 | 100 | 99 | 0 | 99 | 98 | 17 | 79 | 8 | 100 | 99 | 100 | 93 | 0 | 0 | 73 | 99 |
LaOCl | 86 | 76 | 89 | 46 | 0 | 100 | 28 | 88 | 100 | 99 | 0 | 28 | 94 | 0 | 71 | 13 | 100 | 99 | 24 | 92 | 7 | 0 | 96 | 96 |
La2(CO3)3.4H2O | 84 | 25 | 41 | 37 | 28 | 94 | 20 | 0 | 56 | 90 | 0 | 20 | 98 | 1 | 78 | 5 | 100 | 99 | 16 | 11 | 23 | 0 | 48 | 71 |
Ti(CO3)2 | 96 | 93 | 100 | 100 | 99 | 99 | 99 | 98 | 100 | 98 | 79 | 100 | 91 | 98 | 97 | 96 | 24 | 100 | 100 | 92 | 100 | 0 | 99 | 98 |
TiO2 | 96 | 93 | 8 | 4 | 0 | 6 | 0 | 11 | 49 | 97 | 0 | 1 | 97 | 0 | 97 | 62 | 0 | 86 | 0 | 0 | 0 | 30 | 99 | 66 |
La2O(CO3)3.xH2O | 87 | 29 | 53 | 37 | 28 | 100 | 20 | 10 | 58 | 98 | 0 | 25 | 99 | 0 | 79 | 8 | 100 | 99 | 16 | 60 | 26 | 0 | 44 | 74 |
La2O2CO3 | 97 | 92 | 100 | 85 | 21 | 100 | 59 | 98 | 100 | 99 | 0 | 99 | 99 | 34 | 81 | 12 | 100 | 99 | 100 | 92 | 23 | 0 | 87 | 99 |
Claims (36)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40386802P | 2002-08-14 | 2002-08-14 | |
US60/403,868 | 2002-08-14 | ||
US60/430,284 | 2002-12-02 | ||
US60/461,175 | 2003-04-08 | ||
US10/444,774 | 2003-05-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1688511A true CN1688511A (en) | 2005-10-26 |
CN100526219C CN100526219C (en) | 2009-08-12 |
Family
ID=35306292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03824117XA Expired - Lifetime CN100526219C (en) | 2002-08-14 | 2003-08-08 | Rare earth metal compounds, methods of making, and methods of using the same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100526219C (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100398112C (en) * | 2006-03-24 | 2008-07-02 | 辽宁诺康生物制药有限责任公司 | Medicine for treating hyperphosphatemia and its preparing method |
CN103037870A (en) * | 2010-05-12 | 2013-04-10 | 斯派克托姆制药公司 | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
CN104379739A (en) * | 2012-06-05 | 2015-02-25 | 3M创新有限公司 | Lanthanum-based concentration agents for microorganisms |
CN105289521A (en) * | 2015-10-30 | 2016-02-03 | 无锡市新都环保科技有限公司 | Preparation method of surface modified pine needle loaded lanthanum hydroxide phosphorus adsorbent |
US9511091B2 (en) | 2002-05-24 | 2016-12-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
CN108393077A (en) * | 2018-03-28 | 2018-08-14 | 杨帮燕 | A kind of preparation method of high efficiency absorbent-type dephosphorization agent |
CN111393875A (en) * | 2020-03-30 | 2020-07-10 | 内蒙古航天红峡化工有限公司 | Preparation method of titanium dioxide coated rare earth base pearlescent pigment |
CN112912171A (en) * | 2018-10-24 | 2021-06-04 | 三井金属矿业株式会社 | Adsorbent, method for producing same, and molded adsorbent |
CN114524452A (en) * | 2017-10-30 | 2022-05-24 | 浙江大学 | Nano lanthanum carbonate hydrate and preparation method and application thereof |
CN114577782A (en) * | 2020-12-01 | 2022-06-03 | 四川大学 | Method for detecting organic amine through ratio-type catalytic luminescence |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3922331A (en) * | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
US4462970A (en) * | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
FR2623797B2 (en) * | 1987-08-05 | 1990-05-04 | Inst Francais Du Petrole | PROCESS FOR THE CONVERSION OF METHANE INTO HIGHER HYDROCARBONS |
GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
GB9720061D0 (en) * | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
-
2003
- 2003-08-08 CN CNB03824117XA patent/CN100526219C/en not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511091B2 (en) | 2002-05-24 | 2016-12-06 | Spectrum Pharmaceuticals, Inc. | Rare earth metal compounds, methods of making, and methods of using the same |
CN100398112C (en) * | 2006-03-24 | 2008-07-02 | 辽宁诺康生物制药有限责任公司 | Medicine for treating hyperphosphatemia and its preparing method |
US10350240B2 (en) | 2010-05-12 | 2019-07-16 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
CN103037870B (en) * | 2010-05-12 | 2016-05-25 | 斯派克托姆制药公司 | Basic carbonate lanthanum, carbonic acid gas lanthanum and manufacture method and purposes |
US8961917B2 (en) | 2010-05-12 | 2015-02-24 | Spectrum Pharmaceuticals, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
CN103037870A (en) * | 2010-05-12 | 2013-04-10 | 斯派克托姆制药公司 | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
CN104379739A (en) * | 2012-06-05 | 2015-02-25 | 3M创新有限公司 | Lanthanum-based concentration agents for microorganisms |
CN105289521A (en) * | 2015-10-30 | 2016-02-03 | 无锡市新都环保科技有限公司 | Preparation method of surface modified pine needle loaded lanthanum hydroxide phosphorus adsorbent |
CN105289521B (en) * | 2015-10-30 | 2019-03-22 | 无锡市新都环保科技有限公司 | The preparation method of the modified pine needle load lanthanum hydroxide dephosphorization adsorbent in surface |
CN114524452A (en) * | 2017-10-30 | 2022-05-24 | 浙江大学 | Nano lanthanum carbonate hydrate and preparation method and application thereof |
CN108393077A (en) * | 2018-03-28 | 2018-08-14 | 杨帮燕 | A kind of preparation method of high efficiency absorbent-type dephosphorization agent |
CN112912171A (en) * | 2018-10-24 | 2021-06-04 | 三井金属矿业株式会社 | Adsorbent, method for producing same, and molded adsorbent |
CN111393875A (en) * | 2020-03-30 | 2020-07-10 | 内蒙古航天红峡化工有限公司 | Preparation method of titanium dioxide coated rare earth base pearlescent pigment |
CN114577782A (en) * | 2020-12-01 | 2022-06-03 | 四川大学 | Method for detecting organic amine through ratio-type catalytic luminescence |
Also Published As
Publication number | Publication date |
---|---|
CN100526219C (en) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4584830B2 (en) | Method of producing lanthanum oxycarbonate, composition, method of treatment of mammalian hyperphosphatemia, and method of binding phosphate | |
US8715603B2 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
CN110357165B (en) | Process for preparing mixed metal compounds | |
CN1751056A (en) | Ferric organic compounds, uses thereof and methods of making same | |
CN1688511A (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
JP2010059005A (en) | Composite body and method for producing the same | |
EP2194028B1 (en) | Rare earth metal compounds, methods of making, and methods of using the same | |
JP5352416B2 (en) | A blood glucose level lowering agent comprising vanadium-containing aluminum compound as an active ingredient | |
JP5352411B2 (en) | Hypoglycemic agent or pancreatic function enhancing or activating agent comprising hydrotalcite compound particles as an active ingredient | |
ES2907070T3 (en) | Rare earth metal compounds, methods of manufacture and methods of use thereof | |
JP2011084491A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1082242 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1082242 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: GUANGPU PHARMACEUTICAL CO. Free format text: FORMER NAME: ALTAIRNANO INC. |
|
CP03 | Change of name, title or address |
Address after: American California Patentee after: Spectrum pharmaceuticals Address before: Nevada Patentee before: ALTAIRNANO, Inc. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210924 Address after: California, USA Patentee after: Unisexivir treatment Co. Address before: California, USA Patentee before: Spectrum pharmaceuticals |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20090812 |
|
CX01 | Expiry of patent term |